Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Munck

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Therapeutics|August 14, 2021
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal CancerNyree Crawford, Katie J Stott, Tamas Sessler, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.
The Journal of Clinical Investigation|October 4, 2019
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapyCatherine E Willoughby, Yanyan Jiang, Huw D Thomas, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Therapeutics|August 14, 2021
Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal CancerNyree Crawford, Katie J Stott, Tamas Sessler, et al.
Molecular Cancer Therapeutics|May 12, 2012
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3KJoanne M Munck, Michael A Batey, Yan Zhao, et al.
ACS Medicinal Chemistry Letters|July 21, 2015
Fragment-Based Discovery of Potent and Selective DDR1/2 InhibitorsChristopher W Murray, Valerio Berdini, Ildiko M Buck, et al.
Journal of Medicinal Chemistry|August 10, 2018
A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660)Christopher N Johnson, Jong Sook Ahn, Ildiko M Buck, et al.
The Journal of Clinical Investigation|October 4, 2019
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapyCatherine E Willoughby, Yanyan Jiang, Huw D Thomas, et al.
Molecular Cancer Therapeutics|July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKJoanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry|May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Pageof 4